A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.

Trial Profile

A Multicentre, International, Randomised, Parallel Group, Double Blind Study to Evaluate Cardiovascular Safety of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Linagliptin (Primary) ; Glimepiride
  • Indications Cardiovascular disorders; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms CAROLINA
  • Sponsors Boehringer Ingelheim Pharmaceuticals; Unilfarma
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Jun 2016 Planned number of patients changed from 6000 to 6115.
    • 21 Jun 2016 Planned End Date changed from 1 Sep 2018 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top